Oppenheimer Sees Buying Opportunity in ADMA Biologics (ADMA) Despite Expected Prolonged Weakness
Tweet Send to a Friend
Oppenheimer analyst Leland Gershell reiterated an Outperform rating and $14.00 price target on ADMA Biologics (NASDAQ: ADMA) the share price ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
